Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

Skoulidis et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69d80ec645af6083e6ae2c32 — DOI: https://doi.org/10.1158/2159-8290.cd-14-1236

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Coordinated Regulation of Cell Cycle Transcripts by p53-Inducible microRNAs, miR-192 and miR-215· 2008 · 352 citations
2. <i>ALK</i> in Lung Cancer: Past, Present, and Future· 2013 · 462 citations
3. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones· 2011 · 264 citations
4. BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).· 2013 · 8 citations
5. K ⁺ Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension· 2011 · 977 citations